PH12017501989B1 - Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient - Google Patents
Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredientInfo
- Publication number
- PH12017501989B1 PH12017501989B1 PH1/2017/501989A PH12017501989A PH12017501989B1 PH 12017501989 B1 PH12017501989 B1 PH 12017501989B1 PH 12017501989 A PH12017501989 A PH 12017501989A PH 12017501989 B1 PH12017501989 B1 PH 12017501989B1
- Authority
- PH
- Philippines
- Prior art keywords
- cancer
- kinases
- preventing
- diseases
- heteroaryl derivative
- Prior art date
Links
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 title abstract 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 206010001889 Alveolitis Diseases 0.000 abstract 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 206010020850 Hyperthyroidism Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 208000031845 Pernicious anaemia Diseases 0.000 abstract 1
- 206010051986 Pneumatosis Diseases 0.000 abstract 1
- 206010035664 Pneumonia Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000010001 Silicosis Diseases 0.000 abstract 1
- 208000021386 Sjogren Syndrome Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000009267 bronchiectasis Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 208000007451 chronic bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 abstract 1
- 208000018212 fibroblastic neoplasm Diseases 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000037819 metastatic cancer Diseases 0.000 abstract 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000036473 myasthenia Effects 0.000 abstract 1
- 201000008968 osteosarcoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 208000008423 pleurisy Diseases 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150086372 | 2015-06-18 | ||
| KR1020160067210A KR101845931B1 (ko) | 2015-06-18 | 2016-05-31 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| PCT/KR2016/005798 WO2016204429A1 (ko) | 2015-06-18 | 2016-06-01 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12017501989A1 PH12017501989A1 (en) | 2018-03-26 |
| PH12017501989B1 true PH12017501989B1 (en) | 2024-01-17 |
Family
ID=57724790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2017/501989A PH12017501989B1 (en) | 2015-06-18 | 2016-06-01 | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10526337B2 (enExample) |
| EP (1) | EP3312175B1 (enExample) |
| JP (1) | JP6808905B2 (enExample) |
| KR (1) | KR101845931B1 (enExample) |
| CN (1) | CN107690433B (enExample) |
| AU (1) | AU2016279661B2 (enExample) |
| CA (1) | CA2979815C (enExample) |
| ES (1) | ES2816050T3 (enExample) |
| HU (1) | HUE052332T2 (enExample) |
| MX (1) | MX385704B (enExample) |
| MY (1) | MY189345A (enExample) |
| PH (1) | PH12017501989B1 (enExample) |
| PL (1) | PL3312175T3 (enExample) |
| PT (1) | PT3312175T (enExample) |
| RU (1) | RU2719367C2 (enExample) |
| SG (1) | SG11201707448SA (enExample) |
| TW (1) | TWI616446B (enExample) |
| ZA (1) | ZA201707096B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200055116A (ko) * | 2018-01-10 | 2020-05-20 | 보령제약 주식회사 | Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| KR102363043B1 (ko) * | 2018-01-12 | 2022-02-15 | 보령제약 주식회사 | Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| CN111018834B (zh) * | 2018-10-10 | 2022-07-15 | 成都理工大学 | 作为PPAR-γ调节剂的氨基嘧啶丁烯酮衍生物 |
| KR20200129705A (ko) * | 2019-05-09 | 2020-11-18 | 보령제약 주식회사 | 무정형의 pi3k 저해제 및 이를 포함하는 약학적 조성물 |
| KR20200129704A (ko) * | 2019-05-09 | 2020-11-18 | 보령제약 주식회사 | Pi3k 저해제의 결정다형 및 이의 제조방법 |
| KR102338609B1 (ko) * | 2019-05-20 | 2021-12-14 | 보령제약 주식회사 | 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물 |
| CN112194659A (zh) | 2019-07-08 | 2021-01-08 | 浙江海正药业股份有限公司 | 炔类衍生物及其制备方法和用途 |
| KR20210115375A (ko) * | 2020-03-12 | 2021-09-27 | 보령제약 주식회사 | Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물 |
| WO2021201574A1 (ko) * | 2020-03-31 | 2021-10-07 | 보령제약 주식회사 | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 |
| CN113512042B (zh) * | 2020-04-09 | 2024-06-11 | 成都赜灵生物医药科技有限公司 | 取代喹唑啉-4-酮类化合物及其制备方法和用途 |
| CN113527231A (zh) * | 2020-04-15 | 2021-10-22 | 深圳华大生命科学研究院 | 杂环取代腔肠素类化合物的合成方法 |
| WO2022005175A1 (ko) * | 2020-06-30 | 2022-01-06 | 보령제약 주식회사 | Pi3k 저해제로서의 화합물의 제조방법 및 이의 제조를 위한 중간체 화합물 |
| KR20240093519A (ko) * | 2021-11-03 | 2024-06-24 | 주식회사 보령 | Pi3k 및 dna-pk 이중 저해제를 포함하는 말초 t 세포 림프종의 예방 또는 치료용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1277738A (en) | 1916-04-03 | 1918-09-03 | American Can Co | Sardine-can. |
| JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
| MXPA05005477A (es) | 2002-11-21 | 2005-07-25 | Chiron Corp | Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer. |
| UA81790C2 (uk) * | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| TW200938542A (en) * | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| UY32743A (es) | 2009-06-25 | 2010-12-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| SG10201407012XA (en) * | 2009-10-29 | 2014-11-27 | Genosco | Kinase inhibitors |
| WO2014015523A1 (en) | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| CN104151311B (zh) | 2014-01-13 | 2017-01-04 | 华中师范大学 | 一类稠环化合物或其药学上可接受的盐及其制备方法和应用 |
-
2016
- 2016-05-31 KR KR1020160067210A patent/KR101845931B1/ko active Active
- 2016-06-01 MY MYPI2017001544A patent/MY189345A/en unknown
- 2016-06-01 MX MX2017014478A patent/MX385704B/es unknown
- 2016-06-01 PH PH1/2017/501989A patent/PH12017501989B1/en unknown
- 2016-06-01 PL PL16811842T patent/PL3312175T3/pl unknown
- 2016-06-01 JP JP2017565779A patent/JP6808905B2/ja active Active
- 2016-06-01 HU HUE16811842A patent/HUE052332T2/hu unknown
- 2016-06-01 ES ES16811842T patent/ES2816050T3/es active Active
- 2016-06-01 PT PT168118420T patent/PT3312175T/pt unknown
- 2016-06-01 CA CA2979815A patent/CA2979815C/en active Active
- 2016-06-01 AU AU2016279661A patent/AU2016279661B2/en active Active
- 2016-06-01 CN CN201680030953.XA patent/CN107690433B/zh active Active
- 2016-06-01 RU RU2017140446A patent/RU2719367C2/ru active
- 2016-06-01 SG SG11201707448SA patent/SG11201707448SA/en unknown
- 2016-06-01 US US15/567,692 patent/US10526337B2/en active Active
- 2016-06-01 EP EP16811842.0A patent/EP3312175B1/en active Active
- 2016-06-15 TW TW105118848A patent/TWI616446B/zh active
-
2017
- 2017-10-19 ZA ZA2017/07096A patent/ZA201707096B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017014478A (es) | 2018-03-01 |
| US10526337B2 (en) | 2020-01-07 |
| MX385704B (es) | 2025-03-18 |
| SG11201707448SA (en) | 2017-10-30 |
| PH12017501989A1 (en) | 2018-03-26 |
| CA2979815C (en) | 2023-10-24 |
| ZA201707096B (en) | 2018-11-28 |
| KR101845931B1 (ko) | 2018-04-05 |
| US20180105527A1 (en) | 2018-04-19 |
| BR112017025518A2 (pt) | 2018-08-07 |
| KR20160150006A (ko) | 2016-12-28 |
| PT3312175T (pt) | 2020-09-29 |
| AU2016279661A1 (en) | 2017-09-14 |
| JP6808905B2 (ja) | 2021-01-06 |
| PL3312175T3 (pl) | 2021-01-11 |
| MY189345A (en) | 2022-02-05 |
| TW201712010A (zh) | 2017-04-01 |
| AU2016279661B2 (en) | 2020-05-07 |
| RU2017140446A3 (enExample) | 2019-10-29 |
| HUE052332T2 (hu) | 2021-04-28 |
| ES2816050T3 (es) | 2021-03-31 |
| EP3312175A4 (en) | 2018-12-12 |
| EP3312175A1 (en) | 2018-04-25 |
| TWI616446B (zh) | 2018-03-01 |
| EP3312175B1 (en) | 2020-07-22 |
| RU2017140446A (ru) | 2019-05-21 |
| CN107690433B (zh) | 2021-04-09 |
| JP2018522852A (ja) | 2018-08-16 |
| CA2979815A1 (en) | 2016-12-22 |
| HK1250714A1 (zh) | 2019-01-11 |
| RU2719367C2 (ru) | 2020-04-17 |
| CN107690433A (zh) | 2018-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501989A1 (en) | Heteroaryl derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition for preventing or treating diseases associated with pi3 kinases, containing same as active ingredient | |
| IL275379B2 (en) | Benzylamino-converted pyridopyrimidinones and novel antecedents as sos1 inhibitors | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2015528447A5 (enExample) | ||
| PH12017500635A1 (en) | Aminopyridyloxypyrazole compounds | |
| MX2019005526A (es) | Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa. | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| NZ711424A (en) | Pyridine derivatives as soft rock inhibitors | |
| JP2016508505A5 (enExample) | ||
| MX2022000826A (es) | Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton. | |
| JP2010501572A5 (enExample) | ||
| JO2958B1 (en) | Salts 3,2-dihydroimidazo [2.1 C-] quinazolin substituted | |
| HK1251471A1 (zh) | 用於治疗肺的癌症的多核苷酸toll样受体9激动剂的肺内施用 | |
| NZ726365A (en) | Combinations for treating cancers | |
| NZ628392A (en) | Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease | |
| NZ722345A (en) | Pyrazolone compounds and uses thereof | |
| JP2017507175A5 (enExample) | ||
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| MX2017010949A (es) | Derivados de 2-aminopiridina como antagonistas del receptor a2b de adenosina y ligandos del receptor mt3 de melatonina. | |
| RU2011153613A (ru) | Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет | |
| JP2019506382A5 (enExample) | ||
| MX2018004879A (es) | Nuevos derivados de piridona y su uso como inhibidores de quinasas. | |
| MY190027A (en) | P38 map kinase inhibiting indanyl urea compounds | |
| CN113227080A (zh) | 2,4-二氨基嘧啶衍生物 | |
| JP2018526375A5 (enExample) |